DEPTOR and cancer: However, in response to treatment with genotoxic agents, such as doxorubicin, DEPTOR expression was dramatically enhanced by activated p53, leading to cancer cell resistance to doxorubicin by relieving feedback inhibition from S6K1 to IRS1, thus activating AKT.